GlassScriptPhysician profile
Marven Gerel Cabling
NPI 1063674265
$16,871.44
in general payments reported to CMS, 2019-2025
29 companies · $6,893 in 2025
The $6,893 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $35.98 · 2021: $1,418 · 2022: $939 · 2023: $170 · 2024: $6,020 · 2025: $6,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $42.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,040.80 |
| Education | $42.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,521.25 | 2019-2025 | |
| Ucb, INC. | $1,765.79 | 2022-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $1,609.31 | 2021-2023 | Krystexxa |
| Amgen INC. | $1,557.36 | 2019-2025 | Tavneos, Otezla, Otezla |
| Ani Pharmaceuticals, INC. | $862.32 | 2024-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $721.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $688.89 | 2019-2025 | |
| Janssen Biotech, INC. | $672.50 | 2019-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $658.08 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $654.27 | 2022-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $578.25 | 2022-2025 | Lupkynis |
| Lilly USA, LLC | $483.90 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Astrazeneca Pharmaceuticals LP | $483.85 | 2024-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $346.88 | 2019-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $323.80 | 2019-2025 | Orencia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.88 | 2024-2025 | Ofev |
| Radius Health, INC. | $250.62 | 2019-2025 | Tymlos |
| Janssen Scientific Affairs, LLC | $237.50 | 2019-2022 | |
| Kyowa Kirin, INC. | $192.67 | 2024-2025 | Crysvita |
| Organon LLC | $177.44 | 2024-2025 | Hadlima, Renflexis |
| Kiniksa Pharmaceuticals International, Plc | $164.21 | 2024 | Arcalyst |
| Genzyme Corporation | $161.62 | 2024-2025 | |
| Pacira Therapeutics, INC. | $124.37 | 2019 | |
| Fresenius Kabi USA, LLC | $123.81 | 2024-2025 | Idacio |
| Sanofi-Aventis U.S. LLC | $89.99 | 2022 | |
| Genentech USA, INC. | $77.83 | 2019-2022 | |
| Sobi, INC | $26.38 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.22 | 2024 | |
| Novo Nordisk INC | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marven Gerel Cabling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.